Medical Genomics Holds Key to Developing Therapy for Parkinson’s Disease

0
226

The genomics has begun to influence medicines widely and bioinformatics has secured its position as the main factor in the development of novel medical approaches. However, how medical genomics actually works, is still not very clear. A team of scientists at the Centre for Genomic Regulation (CRG), Barcelona, together with researchers at the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and the Barcelona Supercomputing Centre (BSC), have displayed a clear illustration of how genomics is changing the way medicines are currently known across the world.

The team of researchers is led by Gian Gaetano Tartaglia, an ICREA research professor at the CRG. Researchers are using genomics to develop the understanding of people about Parkinson´s disease. According to a report in Nucleic Acids Research, the team has already found out a mechanism that manages the expressions of alpha-synuclein, which is an important protein related to multiple system atrophy (MSA) and Parkinson´s disease. Parkinson´s is one of the most common human neurodegenerative disorder next only to Alzheimer´s. It is a multi-factorial disorder, wherein, aging, genetic susceptibility, and environmental factors congregate to cause neurodegeneration. The pathological symbol of this disorder is the buildup of alpha-synuclein, which, subsequently, results in the frequent death of cells and various issues in neurotransmission.

To understand how this protein is produced, the team projected exchanges between the alpha-synuclein gene and various other factors found in neurons. With these predictions, these researchers and the Fina Martí team at IDIBAPS, could screen and authenticate the candidates in vivo (with mice), in vitro (through cell culture), and ex vivo (by utilizing samples of human brain from dead patients) and then the factors were considered to be relevant for the forming of Parkinson´s disease and MSA or not.

Leave a Reply